image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 2.72
1.12 %
$ 4.06 M
Market Cap
-2.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one EVOK stock under the worst case scenario is HIDDEN Compared to the current market price of 2.72 USD, Evoke Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one EVOK stock under the base case scenario is HIDDEN Compared to the current market price of 2.72 USD, Evoke Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one EVOK stock under the best case scenario is HIDDEN Compared to the current market price of 2.72 USD, Evoke Pharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EVOK

image
$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
10.2 M REVENUE
97.84%
-5.2 M OPERATING INCOME
29.97%
-5.35 M NET INCOME
31.31%
-5.46 M OPERATING CASH FLOW
-9.50%
0 INVESTING CASH FLOW
0.00%
14.3 M FINANCING CASH FLOW
12100.33%
3.08 M REVENUE
-6.90%
-1.3 M OPERATING INCOME
-9.05%
-1.31 M NET INCOME
-9.51%
-998 K OPERATING CASH FLOW
19.56%
0 INVESTING CASH FLOW
0.00%
25 K FINANCING CASH FLOW
-99.29%
Balance Sheet Evoke Pharma, Inc.
image
Current Assets 17.2 M
Cash & Short-Term Investments 13.6 M
Receivables 2.42 M
Other Current Assets 1.22 M
Non-Current Assets 281 K
Long-Term Investments 0
PP&E 154 K
Other Non-Current Assets 127 K
77.61 %13.82 %6.97 %Total Assets$17.5m
Current Liabilities 10.4 M
Accounts Payable 2.34 M
Short-Term Debt 5.06 M
Other Current Liabilities 2.98 M
Non-Current Liabilities 101 K
Long-Term Debt 101 K
Other Non-Current Liabilities 0
22.34 %48.27 %28.43 %Total Liabilities$10.5m
EFFICIENCY
Earnings Waterfall Evoke Pharma, Inc.
image
Revenue 10.2 M
Cost Of Revenue 357 K
Gross Profit 9.89 M
Operating Expenses 15.1 M
Operating Income -5.2 M
Other Expenses 148 K
Net Income -5.35 M
12m12m10m10m8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)10m(357k)10m(15m)(5m)(148k)(5m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
96.52% GROSS MARGIN
96.52%
-50.77% OPERATING MARGIN
-50.77%
-52.22% NET MARGIN
-52.22%
-0.00% ROE
-0.00%
-30.55% ROA
-30.55%
-42.66% ROIC
-42.66%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Evoke Pharma, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.35 M
Depreciation & Amortization 0
Capital Expenditures 0
Stock-Based Compensation 773 K
Change in Working Capital -1.4 M
Others 518 K
Free Cash Flow -5.46 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Evoke Pharma, Inc.
image
Wall Street analysts predict an average 1-year price target for EVOK of $18 , with forecasts ranging from a low of $18 to a high of $18 .
EVOK Lowest Price Target Wall Street Target
18 USD 561.76%
EVOK Average Price Target Wall Street Target
18 USD 561.76%
EVOK Highest Price Target Wall Street Target
18 USD 561.76%
Price
Max Price Target
Min Price Target
Average Price Target
1818161614141212101088664422Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Evoke Pharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
180 USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. globenewswire.com - 1 month ago
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA. globenewswire.com - 2 months ago
evoke makes a steady exit from the Q1 starting gate Evoke PLC (LSE:EVOK) has kicked off 2025 with a steady start, reporting first-quarter revenue of £437.00 million—up 1% on last year and pretty much bang on with what it had guided. So far this year, revenue is up around 4%, and the company says it's still aiming for full-year growth in the 5-9% range. proactiveinvestors.co.uk - 2 months ago
William Hill owner Evoke falls at the first-quarter update Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025.  Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year. proactiveinvestors.co.uk - 3 months ago
Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Daniel Kontoh-Boateng – DKB Partners Matt D'Onofrio – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, GIMOTI, EVERSANA Mark Kowieski – Chief Financial Officer Conference Call Participants Yale Jen – Laidlaw & Company Operator Good afternoon, and welcome to the Evoke Pharma Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently all callers have been placed in a listen-only mode and following management's prepared remarks, the call will be opened for your questions. seekingalpha.com - 3 months ago
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif. globenewswire.com - 3 months ago
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes. globenewswire.com - 4 months ago
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke's commercial strategy and growth potential. globenewswire.com - 4 months ago
William Hill owner Evoke expects earnings to beat market forecasts Expect shares in William Hill owner Evoke PLC to get off to a strong start when the market opens. That's because the bookmaker said full-year earnings for 2024 will surpass market expectations, with strong double-digit revenue growth in the fourth quarter driven by its online business. proactiveinvestors.co.uk - 5 months ago
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA's recent update regarding domperidone supply. globenewswire.com - 6 months ago
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company's robust intellectual property estate for its innovative GIMOTI® (metoclopramide) nasal spray. globenewswire.com - 7 months ago
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year globenewswire.com - 7 months ago
8. Profile Summary

Evoke Pharma, Inc. EVOK

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 4.06 M
Dividend Yield 0.00%
Description Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Contact 420 Stevens Avenue, Solana Beach, CA, 92075 https://www.evokepharma.com
IPO Date Sept. 25, 2013
Employees 3
Officers Mr. Christopher Quesenberry Chief Commercial Officer - Gimoti (TM) Mr. Mark A. Kowieski CPA Chief Financial Officer, Treasurer & Secretary Mr. Matthew J. D'Onofrio MBA Co-Founder, Chief Executive Officer & Director Dr. Marilyn R. Carlson D.M.D., M.D., RAC. Chief Medical Officer